Alemtuzumab in refractory Sézary syndrome.
Sézary syndrome is a primary cutaneous T-cell lymphoma characterized by the triad of erythroderma, lymphadenopathy and circulating atypical cells. The emergence of new molecular targets has enabled the development of drugs such as alemtuzumab, an anti-CD52 monoclonal antibody, which has shown promising results in the treatment of this entity. We report the case of a 70-year-old male with refractory Sézary syndrome in whom treatment with alemtuzumab achieved an 80% skin lesion clearance with complete haematologic and radiologic response. The treatment was discontinued after 4 months due to adverse effects, with the patient showing a sustained response without disease progression after 13 months of follow-up.
Hospital Universitario Reina Sofía - Córdoba, Spain.
Carmen María Alcántara
CM
Reifs
Hospital Universitario Reina Sofía - Córdoba, Spain.
Rafael
R
Salido-Vallejo
Hospital Universitario Reina Sofía - Córdoba, Spain.
Gloria María
GM
Garnacho-Saucedo
Hospital Universitario Reina Sofía - Córdoba, Spain.
Sofía De la
S
Corte-Sánchez
Hospital Universitario Reina Sofía - Córdoba, Spain.
Alberto
A
González-Menchen
Hospital Universitario Reina Sofía - Córdoba, Spain.
Antonio Vélez
AV
García-Nieto
D000368:Aged; D000074323:Alemtuzumab; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000945:Antigens, Differentiation, T-Lymphocyte / Q000378:metabolism; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001772:Blood Cell Count; D006801:Humans; D008297:Male; D012751:Sezary Syndrome / Q000097:blood / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000097:blood / Q000188:drug therapy*; D016896:Treatment Outcome
D061067:Antibodies, Monoclonal, Humanized; D000945:Antigens, Differentiation, T-Lymphocyte; D000970:Antineoplastic Agents; D000074323:Alemtuzumab